个人简介
苏州大学医学部基础医学与生物科学学院，教授，博导。2008年博士毕业；在加拿大玛格丽特公主癌症中心从事博士后研究工作，合作导师为研究中心副院长、UHN副总裁、加拿大健康科学院院士、国际著名的癌症疫苗研发与产业转化专家Christopher J. Paige教授。主要研究方向为：肿瘤免疫、mRNA疫苗、细胞治疗。本人近年来，以第一和通讯身份在发表肿瘤免疫相关的SCI论文10余篇，作为第一发明人获得授权的肿瘤疫苗发明专利2项。主持国家自然科学基金两项、江苏省高校自然科学基金、苏州市自然科学基金横向项目多项。担任国家自然科学基金评审专家，也是多本肿瘤免疫顶级杂志的特约审稿人包括Journal for Immunotherapy of cancer、leukemia、Cancer Letters、Journal of Immunology、Cancer Science、Scientific reports等杂志。
肿瘤免疫、mRNA疫苗
致力于通过肿瘤疫苗、溶瘤病毒等免疫治疗方法的研究，探索肿瘤进程与免疫系统的相互作用。
承担本科生的教学课程：《免疫学》、《医学免疫学》、《Medical Immunology》、《细胞工程》、《基因工程原理与技术》。
承担研究生的教学课程：《细胞与分子免疫学》
1. Xu X, Gan M, Ge Y, Yi C, Feng T, Liu M, Wu C, Chen X, Zhang W*, Zhao L*, Zou J*. Multifaceted glycoadjuvant@AuNPs inhibits tumor metastasis through promoting T cell activation and remodeling tumor microenvironment. J Nanobiotechnology. 2021. 19(1): 376. (Corresponding author)
2. Xu X, Yi C, Yang X, Xu J, Sun Q, Liu Y, Zhao L. Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine. Mol Ther Oncolytics. 2019. 14:213-221. (Corresponding author)
3. Xu Xiaojing, Jin Ziqi, Liu Yonghao, Gong Huanle, Sun Qing, Zhang Weidong, Zhao Lixiang*. Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs. Cancer Letters. 2019. 440: 94~105. (Corresponding author)
4. Mei Yu, Zhao Lixiang#, Yonghao Liu, et al. Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4(+) and CD8(+) T-cell Responses. Cancer Immunology Research. 2017. 5(6):503-514. (Equal contributor)
5. Xu Xiaojing, Mei Yu, Zhao Lixiang*. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy. Cancer Science. 2018.109(2): 279. (Corresponding author)
6. Zhao Lixiang, Mei Yu, Sun Qing, et al. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response. The Journal of Immunology.2014. 193(2): 735-745.
7. Xu Xiaojing, Sun Qing, Yu Xiao,Zhao Lixiang*. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy. Virus Research. 2017. 233:35-41.
8. Xu Xiaojing, Chen Xiang, Gao Song, Zhao Lixiang*. Pathogenicity of FtsK mutant of avian pathogenic Escherichia coli 2016. 60(1): 13~18. (Corresponding author）
9. Sun Qing#, Zhao Lixiang#, Song Qingqing, et al. Hybrid- and complex-type N-glycans are notessential for Newcastle disease virus infection and fusion of host cells. Glycobiology. 2012. (Equal contributor)
10. Zhao L, Liu H. Newcastle disease virus: a promising agent for tumor immunotherapy. Clin Exp Pharmacol Physiol. 2012; 39(8): 725-30.
11. Zhao L, Gao S, Huan H,Xu X, Zhu X, Yang W, Gao Q, Liu X.Comparison of virulence factors and expression of specific genes between uropathogenic Escherichia coli and avian pathogenic E. coli in a murine urinary tract infection model and a chicken challenge model. Microbiology. 2009; 155: 1634-1644.
发明专利
1. 赵李祥，梅雨，刘海燕。以减毒沙门氏菌为载体的口服肿瘤疫苗的制备及其应用。专利号：CN201310600070.6 （授权时间：2015年）
2. 赵李祥，刘海燕，文丽君。一种重组新城疫病毒修饰的自体肿瘤疫苗的制备及其应用。专利号：CN201110188380.2（授权时间：2013年）
个人简介
苏州大学医学部基础医学与生物科学学院，教授，博导。2008年博士毕业；在加拿大玛格丽特公主癌症中心从事博士后研究工作，合作导师为研究中心副院长、UHN副总裁、加拿大健康科学院院士、国际著名的癌症疫苗研发与产业转化专家Christopher J. Paige教授。主要研究方向为：肿瘤免疫、mRNA疫苗、细胞治疗。本人近年来，以第一和通讯身份在发表肿瘤免疫相关的SCI论文10余篇，作为第一发明人获得授权的肿瘤疫苗发明专利2项。主持国家自然科学基金两项、江苏省高校自然科学基金、苏州市自然科学基金横向项目多项。担任国家自然科学基金评审专家，也是多本肿瘤免疫顶级杂志的特约审稿人包括Journal for Immunotherapy of cancer、leukemia、Cancer Letters、Journal of Immunology、Cancer Science、Scientific reports等杂志。
肿瘤免疫、mRNA疫苗
致力于通过肿瘤疫苗、溶瘤病毒等免疫治疗方法的研究，探索肿瘤进程与免疫系统的相互作用。
承担本科生的教学课程：《免疫学》、《医学免疫学》、《Medical Immunology》、《细胞工程》、《基因工程原理与技术》。
承担研究生的教学课程：《细胞与分子免疫学》
1. Xu X, Gan M, Ge Y, Yi C, Feng T, Liu M, Wu C, Chen X, Zhang W*, Zhao L*, Zou J*. Multifaceted glycoadjuvant@AuNPs inhibits tumor metastasis through promoting T cell activation and remodeling tumor microenvironment. J Nanobiotechnology. 2021. 19(1): 376. (Corresponding author)
2. Xu X, Yi C, Yang X, Xu J, Sun Q, Liu Y, Zhao L. Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine. Mol Ther Oncolytics. 2019. 14:213-221. (Corresponding author)
3. Xu Xiaojing, Jin Ziqi, Liu Yonghao, Gong Huanle, Sun Qing, Zhang Weidong, Zhao Lixiang*. Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs. Cancer Letters. 2019. 440: 94~105. (Corresponding author)
4. Mei Yu, Zhao Lixiang#, Yonghao Liu, et al. Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4(+) and CD8(+) T-cell Responses. Cancer Immunology Research. 2017. 5(6):503-514. (Equal contributor)
5. Xu Xiaojing, Mei Yu, Zhao Lixiang*. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy. Cancer Science. 2018.109(2): 279. (Corresponding author)
6. Zhao Lixiang, Mei Yu, Sun Qing, et al. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response. The Journal of Immunology.2014. 193(2): 735-745.
7. Xu Xiaojing, Sun Qing, Yu Xiao,Zhao Lixiang*. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy. Virus Research. 2017. 233:35-41.
8. Xu Xiaojing, Chen Xiang, Gao Song, Zhao Lixiang*. Pathogenicity of FtsK mutant of avian pathogenic Escherichia coli 2016. 60(1): 13~18. (Corresponding author）
9. Sun Qing#, Zhao Lixiang#, Song Qingqing, et al. Hybrid- and complex-type N-glycans are notessential for Newcastle disease virus infection and fusion of host cells. Glycobiology. 2012. (Equal contributor)
10. Zhao L, Liu H. Newcastle disease virus: a promising agent for tumor immunotherapy. Clin Exp Pharmacol Physiol. 2012; 39(8): 725-30.
11. Zhao L, Gao S, Huan H,Xu X, Zhu X, Yang W, Gao Q, Liu X.Comparison of virulence factors and expression of specific genes between uropathogenic Escherichia coli and avian pathogenic E. coli in a murine urinary tract infection model and a chicken challenge model. Microbiology. 2009; 155: 1634-1644.
发明专利
1. 赵李祥，梅雨，刘海燕。以减毒沙门氏菌为载体的口服肿瘤疫苗的制备及其应用。专利号：CN201310600070.6 （授权时间：2015年）
2. 赵李祥，刘海燕，文丽君。一种重组新城疫病毒修饰的自体肿瘤疫苗的制备及其应用。专利号：CN201110188380.2（授权时间：2013年）